An evidence map of systematic reviews to inform interventions in prediabetes

Canadian Journal of Diabetes

Volumn 36, Issue 5, 2012, Pages 281-291

  Singh, Kavita ^a   Ansari, Mohammed ^a   Galipeau, James ^a   Garritty, Chantelle ^a   Keely, Erin ^a,b   Malcolm, Janine ^a,b   Pratt, Mistrel ^a   Skidmore, Becky ^a   Sorisky, Alexander ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Cardiovascular disease; Diabetes mellitus; Glucose intolerance; Impaired fasting glucose; Impaired glucose tolerance; Prediabetes; Primary prevention

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CHROMIUM; ENALAPRIL; GLIPIZIDE; HEMOGLOBIN A1C; HERBACEOUS AGENT; METFORMIN; NATEGLINIDE; PHENFORMIN; PIOGLITAZONE; PRAVASTATIN; RAMIPRIL; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; TOLBUTAMIDE; TROGLITAZONE; VOGLIBOSE;

ALTERNATIVE MEDICINE; BEHAVIOR MODIFICATION; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; DIABETES EDUCATION; DIET THERAPY; EXERCISE; GLYCEMIC CONTROL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; STOMACH BYPASS; SYSTEMATIC REVIEW (TOPIC); WEIGHT REDUCTION;

EID: 84872658646     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcjd.2012.06.004     Document Type: Review

References (42)

1. de Rezende J, Coslovsky S [Our concept of pre-diabetes]. Rev Ginecol Obstet (Sao Paulo) 1965;117:23-8.
2. Unwin N, Shaw J, Zimmet P, et al. Impaired glucose tolerance and impaired fasting glycemia: the current status on definition and intervention. Diabetic Med 2002;19:708-23.
3. Yates T, Davies M, Khunti K. Preventing type 2 diabetes: can we make the evidence work? Postgrad Med J 2009;85:475-80.
4. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007;30: 753-9.
5. World Health Organization. 2006. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. (available online at http://whqlibdoc.who. int/publications/2006/9241594934_eng.pdf).
6. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32: S1-201.
7. The DECODE Study Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003;26:688-96.
8. The DECODE Study Group. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 2003;26: 61-9.
9. Bertram MY, Vos T. Quantifying the duration of pre-diabetes. Aust.N Z J Public Health 2010;34:311-4.
10. Springer J, Phillips J. 2012. The Institute of Medicine framework and its implications for the advancement of prevention policy, programs and practice. (available online at http://www.ca-sdfsc.org/docs/resources/SDFSC_IOM_Policy.pdf).
11. Hetrick SE, Parker AG, Callahan P, et al. Evidence mapping: illustrating an emerging methodology to improve evidence-based practice in youth mental health. J Eval Clin Pract 2010;16:1025-30.
12. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol 2005;8:19-32.
13. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007;7:10.
14. Grimshaw J, Hill S, Lowe D, et al. 2012. Methods for development. (available online at http://www.cadth.ca/en/resources/rx-for-change/methods-fordevelopment).
15. Aucott L, Poobalan A, Smith WC, et al. Weight loss in obese diabetic and nondiabetic individuals and long-term diabetes outcomes-a systematic review. Diabetes Obes Metab 2004;6:85-94.
16. Curtis J, Wilson C. Preventing type 2 diabetes mellitus. J Am Board Fam Pract 2005;18:37-43.
17. Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007;334:299.
18. Grant SJ, Bensoussan A, Chang D, et al. Chinese herbal medicines for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst Rev; 2009:CD006690.
19. Lily M, Godwin M. Treating prediabetes with metformin: systematic review and meta-analysis. Can Fam Physician 2009;55:363-9.
20. Nield L, Summerbell CD, Hooper L, et al. Dietary advice for the prevention of type 2 diabetes mellitus in adults. Cochrane Database Syst Rev 2008;3: CD005102. 2008.
21. Norris SL, Zhang X, Avenell A, et al. Long-term non-pharmacological weight loss interventions for adults with prediabetes. Cochrane Database Syst Rev 2005;2:CD005270.
22. Norris SL, Carson S, Roberts C. Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis. Curr Diabetes Rev 2007;3:127-40.
23. Norris SL, Kansagara D, Bougatsos C, et al. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2008;148:855-68.
24. Orozco LJ, Buchleitner AM, Gimenez-Perez G, et al. Exercise or exercise and diet for preventing type 2 diabetes mellitus. Cochrane Database Syst Rev; 2008:CD003054.
25. Phung OJ, Sood NA, Sill BE, et al. Oral anti-diabetic drugs for the prevention of Type 2 diabetes. Diabetic Med 2011;28:948-64.
26. Santaguida PL, Balion C, Hunt D, et al. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evid Rep Technol Assess (Summ); 2005:1-11.
27. Tieu J, Coat S, Hague W, et al. Oral anti-diabetic agents for women with preexisting diabetes mellitus/impaired glucose tolerance or previous gestational diabetes mellitus. Cochrane Database Syst Rev; 2010:CD007724.
28. Van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst Rev; 2006:CD005061.
29. Avenell A, Broom J, Brown TJ, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2001;8:iii-iiv.
30. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403.
31. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7.
32. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-803.
33. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
34. van Dieren S, Beulens JW, van der Schouw YT, et al. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil 2010;17(suppl 1):S3-8.
35. Cobble ME, Peters AL. Clinical practice in type 2 diabetes: after metformin and lifestyle, then what? J Fam Pract 2009;58:S7-14.
36. Tsai SP, Wen CP, Chan HT, et al. The effects of pre-disease risk factors within metabolic syndrome on all-cause and cardiovascular disease mortality. Diabetes Res Clin Pract 2008;82:148-56.
37. Garber AJ, Handelsman Y, Einhorn D, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemiadwhen do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract 2008; 14:933-46.
38. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003;289:2560-72.
39. Tsai SP, Wen CP, Chan HT, et al. The effects of pre-disease risk factors within metabolic syndrome on all-cause and cardiovascular disease mortality. Diabetes Res Clin Pract 2008;82:148-56.
40. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
41. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 2007;176:1113-20.
42. Green S, Higgins J, editors. Glossary. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. 2005. (available online at http://www.cochrane. org/resources/handbook/).